EP0167567A1 - Treatment of metastasis - Google Patents

Treatment of metastasis

Info

Publication number
EP0167567A1
EP0167567A1 EP19850900412 EP85900412A EP0167567A1 EP 0167567 A1 EP0167567 A1 EP 0167567A1 EP 19850900412 EP19850900412 EP 19850900412 EP 85900412 A EP85900412 A EP 85900412A EP 0167567 A1 EP0167567 A1 EP 0167567A1
Authority
EP
European Patent Office
Prior art keywords
forskolin
analogs
group
hydroxy
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19850900412
Other languages
German (de)
French (fr)
Inventor
Kailash C. Agarwal
Robert E. Parks, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brown University Research Foundation Inc
Original Assignee
Brown University Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brown University Research Foundation Inc filed Critical Brown University Research Foundation Inc
Publication of EP0167567A1 publication Critical patent/EP0167567A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom

Definitions

  • This invention concerns methods and compositions for the treatment of tumor-induced metastasis, in particular, hematogeneous metastasis.
  • the U. S. Government has rights in this invention pursuant to grants Nos. CA 13943 and CA 07340 provided by the U. S. Public Health Service.
  • the hematogeneous metastatic process begins with the detachment of tumor cells from the primary tumor followed by intravasation with direct shedding of tumor cells into circulation. Although most tumor cells in circulation are quickly destroyed by various mechanisms, a few viable cells may be arrested in the microva ⁇ culature or otherwise may adher to endothelial surfaces.
  • thrombotic material consisting of platelets, erythrocytes and fibrin. Thrombus formation appears to be a significant event in the establishment of tumor colonies in the capillary beds of various organs. Blood platelets also appear to play an important role in tumor metastasis; it has been demonstrated that many metastasizing tumor cell lines induce platelet aggregation both in vitro and in vivo. Furthermore, upon aggregation, platelets release a substance or substances which promote tumor growth.
  • anticoagulants and anti-aggregating agents such as heparin, warfarin (Hagmar and Norrby, Vol. 5 Int. J. Cancer, pp. 72-84, [1970]; Lione and Bosmann, Vol. 2 Cell Biol. Int. Res., pp. 81-86 [1972]; Hoover and Ketcham, Vol. 35 Cancer, pp. 5-14 [1975]); aspirin (Gasic et al., Lancet II, pp. 932-933 [1972]; Wood and Hilgard, Lancet II, pp. 1416-1416 [1972]; Hilgard et al., Vol.
  • PKI 2 prostacyclin 2
  • PKI 2 a potent inhibitor of platelet aggregation
  • Forskolin compounds are generally defined as labdane diterpenoids having the general formula:
  • R 1 is hydrogen or a hydroxy or alkoxy, sulfonate or carbonate group
  • R 2 is a hydroxy, carbonate, acetyl, or acetoxy or alkanoyl group
  • R 3 is a hydroxy, carbonate, acetyl or acetoxy group
  • R 4 is hydrogen or a hydroxy or alkoxy, sulfonate or carbonate group
  • R 5 is either double-bonded oxygen or separately bound hydrogen and hydroxy groups
  • R 6 is a lower alkene or oxygen.
  • the forskolin blocks human platelet aggregation (induced by a wide variety of aggregation stimulators) by stimulating membrane adenylate cyclase thereby increasing several-fold the intracellular concentrations of cyclic AMP and inhibiting the tumor cell-platelet interactions which seem to play a role in tumor metastasis.
  • Forskolin may be unique in its action and perhaps interacts directly with the catalytic subunit of adenylate cyclase.
  • forskolin's high activity coupled with its low toxicity suggest that it can be a highly effective agent in reducing metastasis.
  • forskolin analogs with similar properties include various modifications of the groups labeled R 1 to R 6 in formula I above.
  • the 6-hydroxy group may be acetylated.
  • the 7-acetyl group may be removed or replaced by r-alkaroyl or tosyl groups.
  • the delta 14 15 bond may be substituted by oxygen.
  • 6,7-dicarbonate may also be effective.
  • the 6-acetyl-7-deacetyl derivative also appears to be active as do compounds where the chain length of the 6-alkanoyl group is increased or diethylarainocthyl groups are introduced at the 1 -position.
  • 7-Deacetyl-11-deoxo-11 beta-hydroxyforskolin and 1-methyl-6 acetyl-7 deacetyl derivatives also appear to be pharmacologically active.
  • the forskolin compounds described above may be administered alone or in conjunction with other agents.
  • the forskolin compounds may be combined with nucleoside transport inhibitors which retard the uptake of adenosine by red blood cells and the like; such inhibitors include p-nitrobenzylthioinosine and dilazep.
  • Our compounds may also be combined with agents that block the action of cAMP phosphodiesterase in converting cAMP to AMP, such as theophylline analogs, or compounds that both inhibit nucleoside transport and block cAMP conversion, such as dipyridamole and its analogs (i.e., RA-233), oxagrelate and papaverine.
  • the forskolin compounds may be combined with other compounds that act upon adenylate cyclase in different fashions to create a synergistic effect; such compounds include adenosine analogs and prostacyclins.
  • Fig. 1 is a graph plotting in vitro human platelet aggregation induced by the melanoma cells.
  • A control
  • B after treatment of platelet-rich plasma with forskolin.
  • Figs. 2a-2d are photographs comparing representative lung specimens from forskolin-treated and untreated mice.
  • Example I A mouse melanoma subline, B16-F10, (highly metastatic to the lungs) was obtained from EG & G Mason Research Institute, Worcester, MA, and adapted to growth in cell culture. The cultured cells were harvested by 1 min of trypsinization (0.25% trypsin-0.1% EDTA) or with the use of a rubber policeman, washed gently three times with Hank's balanced salts solution (HBBS, free of Ca and Mg ++ ). The cell viability determined by Trypan Blue exclusion ranged from 70-95% in the separate experiments. Freshly drawn whole blood from healthy adult human donors was anticoagulated with heparin (5 units/ml). The donors had not ingested antiplatelet drugs for at least 10 days.
  • Platelet-rich plasma was separated by centrifugation of the whole blood and platelet aggregation was measured in PRP by recording the increase in light transmission after the addition of the tumor cells.
  • Washed B16-F10 cell suspensions (2 x 10 7 /ml) were treated with potato apyrase (1 unit/ml) for about 5 min to degrade exogenous adenine nucleotides. Fifty microliters of the cell suspension was then added to the platelet-rich plasma after an incubation of 5 min with (A) 5 microliters DMSO (10% in saline) (Control) or (B) 5 microliters forskolin (200 micro Molars in DMSO 10% in saline).
  • Fig. 1 shows that B16-F10 cells (2 x 10 6 /ml) induced human blood platelet aggregation after a lag of about 1 min. However, if the PRP was preincubated (5 min) with the low concentration of forskolin (2 micromolars), the tumor cell-induced platelet aggregation was strongly blocked.
  • Example II Intravenous tail vein injections of B16-F10 cells (2 or 3 x 10 5 cell/mouse) to C57BL/6 mice (5-8 weekB old, 6-9 mice/group), produced a large number of pulmonary tumor foci after 9 or 14 days. However, if the mice were treated with a single intraperitoneally dose of forskolin (82 micrograms/mouse, i.e. 4-5 mg/kg) given 30 or 60 min before the tumor cell injections, reductions in tumor colonization of greater than 70 percent were observed. Similar results were seen in three separate experiments. Washed B16-F10 tumor cells (2 or 3 x 10 5 ) in 100 microliters Hanks balanced salts solution were injected from the tail vein 60 min (Exp. 1) or 30 min (Exp.
  • Fig. 2 presents typical specimens of lungs from untreated and forskolin-treated mice of experiments 2 and 3. Examination under a dissecting microscope revealed that the tumor foci in the forskolin-treated mice were smaller and more superficial than in the untreated mice, which were larger and more deeply embedded. A summary of these experiments is provided in Table 1 below.
  • EXAMPLE IV The in vivo experimental procedure of Example II above was also repeated using a combination of forskolin and oxagrelate. Intraperitoneal injections of the combination (oxagrelate: 40-45 mb/kg and forskolin: 1-1.5 mg/kg) 30 minutes before tail vein injections of the B16-F10 tumor cells reduced tumor colonization in the lungs of the mice 40 to 70 percent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un procédé de réduction de l'incidence de métastases chez des patients victimes de tumeurs consiste à administrer de la forskoline ou ses analogues, puissants inhibiteurs de l'agglutination de thrombocytes. Les composés de forskoline sont définis généralement comme diterpénoïdes de labdane et présentent la formule générale (I). Ces composés peuvent être administrés seuls ou en combinaison avec d'autres inhibiteurs de l'agglutination de thrombocytes.One method of reducing the incidence of metastasis in tumor patients is to administer forskolin or its analogs, potent inhibitors of thrombocyte agglutination. Forskolin compounds are generally defined as labdane diterpenoids and have the general formula (I). These compounds can be administered alone or in combination with other inhibitors of thrombocyte agglutination.

Description

TREATMENT OF METASTASIS
Technical Field
This invention concerns methods and compositions for the treatment of tumor-induced metastasis, in particular, hematogeneous metastasis. The U. S. Government has rights in this invention pursuant to grants Nos. CA 13943 and CA 07340 provided by the U. S. Public Health Service.
Background of the Invention
Advances in surgical and radiation treatment of primary tumors have left metastasis as perhaps the most devastating aspect of cancer. In operable cases, primary tumor growth or local recurrence is rarely a cause of death. Instead, at present, roughly one-third of cancer victims with operable tumors ultimately succumb to metastatic disease.
The hematogeneous metastatic process begins with the detachment of tumor cells from the primary tumor followed by intravasation with direct shedding of tumor cells into circulation. Although most tumor cells in circulation are quickly destroyed by various mechanisms, a few viable cells may be arrested in the microvaεculature or otherwise may adher to endothelial surfaces.
While in the boood stream or shortly after adhesion to endotheliurm, intravascular cancer cells become surrounded by thrombotic material consisting of platelets, erythrocytes and fibrin. Thrombus formation appears to be a significant event in the establishment of tumor colonies in the capillary beds of various organs. Blood platelets also appear to play an important role in tumor metastasis; it has been demonstrated that many metastasizing tumor cell lines induce platelet aggregation both in vitro and in vivo. Furthermore, upon aggregation, platelets release a substance or substances which promote tumor growth.
Since tumor cell-platelet interactions play a role in tumor metastasis, several laboratories have examined anticoagulants and anti-aggregating agents, such as heparin, warfarin (Hagmar and Norrby, Vol. 5 Int. J. Cancer, pp. 72-84, [1970]; Lione and Bosmann, Vol. 2 Cell Biol. Int. Res., pp. 81-86 [1972]; Hoover and Ketcham, Vol. 35 Cancer, pp. 5-14 [1975]); aspirin (Gasic et al., Lancet II, pp. 932-933 [1972]; Wood and Hilgard, Lancet II, pp. 1416-1416 [1972]; Hilgard et al., Vol. 86 Z. Krebsforsch., pp. 243-250 [1976]) and dipyridamole (Hilgard in Interaction of Platelets and Tumor Cells, pp. 143-158, Jameson [ed.] [1982]; Ambrus et al. in Platelets: A Multidisciplinary Approach, pp. 467-48 , de Gaetano [ed.] [1982]) to reduce the incidence of tumor metastasis in experimental animal models. However, the results of many of these studies were inconclusive. Recent reports by Honn et al., 212 Science, pp. 1270-1272 (1981) have shown that i.v. injection of prostacyclin (PGI2), a potent inhibitor of platelet aggregation, reduces pulmonary tumor colonization by tail vein injected B16 amelanotic melanoma cells in mice. There exists a need for new and effective agents for treatment and prevention of metastasis. In particular, agents that are capable of reducing the incidence of metastasis by inhibiting platelet aggregation without harmful side-effects would satisfy a long-felt medical need.
Summary of the Invention
It has been discovered that a method for reducing the incidence of metastasis in tumor victims resides in the administration of forskolin or its analogs which are potent inhibitors of platelet aggregation. Forskolin compounds are generally defined as labdane diterpenoids having the general formula:
where R1 is hydrogen or a hydroxy or alkoxy, sulfonate or carbonate group; where R2 is a hydroxy, carbonate, acetyl, or acetoxy or alkanoyl group; where R3 is a hydroxy, carbonate, acetyl or acetoxy group; where R4 is hydrogen or a hydroxy or alkoxy, sulfonate or carbonate group; where R5 is either double-bonded oxygen or separately bound hydrogen and hydroxy groups; and where R6 is a lower alkene or oxygen.
In particular, we have found that 7 beta-acetoxy-8, 13-epoxy-1 alpha, 6 beta, 9 alpha trihydroxy-labd-14-en-11-one (forskolin) is effective in preventing the metastasis of mouse melanoma tumor cells. This compound is defined by the following formula:
It appears that the forskolin blocks human platelet aggregation (induced by a wide variety of aggregation stimulators) by stimulating membrane adenylate cyclase thereby increasing several-fold the intracellular concentrations of cyclic AMP and inhibiting the tumor cell-platelet interactions which seem to play a role in tumor metastasis.
We have demonstrated that forskolin strongly inhibits the melanoma cell-induced human platelet aggregation in vitro. Additionally, we have shown that forskolin, administered intraperitoneally to live animals prior to tail vein injections of cultured cancer cells, reduced tumor colonization in the lungs by more than 70 percent. Moreover, the inhibitory effects of forskolin in vitro have been shown to be potentiated by the combination of this agent with other anti-aggregating compounds, such as prostaglandin E, and 2-fluoroadenosine (F-Ado).
Our experiments also indicate that forskolin compares favorably with PGI2 when in vivo activity in reducing metastasis is measured. Although PGI2, compared to forskolin on a molar basis, is several hundred-fold more potent in inhibiting the platelet aggregation in vitro, the potencies of PGI2 and forskolin as inhibitors of pulmonary tumor metastasis are similar. According to Honn, doses of PGI2 in the range of 50-200 micrograas/mouse were required to obtain decreases in pulmonary tumor foci of greater than 50 percent. Our studies show that a single dose of forskolin (82 microgram/mouse, i.p.) reduced pulmonary colonization by more than 70 percent. Forskolin may be unique in its action and perhaps interacts directly with the catalytic subunit of adenylate cyclase. Thus, forskolin's high activity coupled with its low toxicity (reported LD 50 values for mice are 105 mg/kg i.p. and 3,100 mg/kg per OS) suggest that it can be a highly effective agent in reducing metastasis.
The invention will next be described in connection with certain preferred embodiments; however, it should be clear that various changes and modifications can be made by those skilled in the art without departing from the spirit and scope of the invention. For example, although the experiments reported herein employed the 7 beta-acetoxy-8, 13-epoxy-1 alpha, 6 beta, 9 alphatrihydroxy-labd-14-en-11-one compound forskolin, various analog compounds can be expected to exhibit similar properties. See generally, Bhat et al., "Structures and Stereochemistry of New Labdane Diterpenoids from Coleus Forskohlii Briq.", Tetrahedron Letters, pp. 1669-1672 (1977); Adnot et al., "Forskolin (a powerful inhibitor of human platelet aggregation)", Vol. 31, Biochemical Pharmacology, pp. 4071-4074 (1982); Bhat et al., "Antihypertensive and Positive Inotropic Diterpene Forskolin: Effects of Structural Modifications on its Activity", Vol. 26, J. Med. Chem., pp. 486-492 (1983) and DeSouza et al., "Forskolin: A Labdane Diterpenoid with Antihypertensive, Positive Inotropic, Platelet Aggregation Inhibitory, and Adenylate Cyclase Activating Properties", Vol. 3, Medicinal Research Reviews, pp. 201-219 (1983), all of which are incorporated herein by reference, for discussions of pharmalogically active forskolin analogs.
Specifically, forskolin analogs with similar properties include various modifications of the groups labeled R1 to R6 in formula I above. The 6-hydroxy group may be acetylated. The 7-acetyl group may be removed or replaced by r-alkaroyl or tosyl groups. The delta 14 15 bond may be substituted by oxygen.
1,9-dideoxyforskolin as well as the 6,7-carbonate and the 1,9:
6,7-dicarbonate may also be effective. The 6-acetyl-7-deacetyl derivative also appears to be active as do compounds where the chain length of the 6-alkanoyl group is increased or diethylarainocthyl groups are introduced at the 1 -position. Moreover, 7-Deacetyl-11-deoxo-11 beta-hydroxyforskolin and 1-methyl-6 acetyl-7 deacetyl derivatives also appear to be pharmacologically active. The forskolin compounds described above may be administered alone or in conjunction with other agents. The forskolin compounds may be combined with nucleoside transport inhibitors which retard the uptake of adenosine by red blood cells and the like; such inhibitors include p-nitrobenzylthioinosine and dilazep. Our compounds may also be combined with agents that block the action of cAMP phosphodiesterase in converting cAMP to AMP, such as theophylline analogs, or compounds that both inhibit nucleoside transport and block cAMP conversion, such as dipyridamole and its analogs (i.e., RA-233), oxagrelate and papaverine. Additionally, the forskolin compounds may be combined with other compounds that act upon adenylate cyclase in different fashions to create a synergistic effect; such compounds include adenosine analogs and prostacyclins.
Brief Description of the Figures
Fig. 1 is a graph plotting in vitro human platelet aggregation induced by the melanoma cells. (A) control (B) after treatment of platelet-rich plasma with forskolin.
Figs. 2a-2d are photographs comparing representative lung specimens from forskolin-treated and untreated mice.
Description of the Preferred Embodiments
The following non-limiting working examples illustrate our invention.
Example I A mouse melanoma subline, B16-F10, (highly metastatic to the lungs) was obtained from EG & G Mason Research Institute, Worcester, MA, and adapted to growth in cell culture. The cultured cells were harvested by 1 min of trypsinization (0.25% trypsin-0.1% EDTA) or with the use of a rubber policeman, washed gently three times with Hank's balanced salts solution (HBBS, free of Ca and Mg++). The cell viability determined by Trypan Blue exclusion ranged from 70-95% in the separate experiments. Freshly drawn whole blood from healthy adult human donors was anticoagulated with heparin (5 units/ml). The donors had not ingested antiplatelet drugs for at least 10 days. Platelet-rich plasma (PRP) was separated by centrifugation of the whole blood and platelet aggregation was measured in PRP by recording the increase in light transmission after the addition of the tumor cells. Washed B16-F10 cell suspensions (2 x 107/ml) were treated with potato apyrase (1 unit/ml) for about 5 min to degrade exogenous adenine nucleotides. Fifty microliters of the cell suspension was then added to the platelet-rich plasma after an incubation of 5 min with (A) 5 microliters DMSO (10% in saline) (Control) or (B) 5 microliters forskolin (200 micro Molars in DMSO 10% in saline). Final concentration of forskolin in PRP (500 microliters) was 2 raicromolars. Fig. 1 shows that B16-F10 cells (2 x 106/ml) induced human blood platelet aggregation after a lag of about 1 min. However, if the PRP was preincubated (5 min) with the low concentration of forskolin (2 micromolars), the tumor cell-induced platelet aggregation was strongly blocked.
Example II Intravenous tail vein injections of B16-F10 cells (2 or 3 x 105 cell/mouse) to C57BL/6 mice (5-8 weekB old, 6-9 mice/group), produced a large number of pulmonary tumor foci after 9 or 14 days. However, if the mice were treated with a single intraperitoneally dose of forskolin (82 micrograms/mouse, i.e. 4-5 mg/kg) given 30 or 60 min before the tumor cell injections, reductions in tumor colonization of greater than 70 percent were observed. Similar results were seen in three separate experiments. Washed B16-F10 tumor cells (2 or 3 x 105) in 100 microliters Hanks balanced salts solution were injected from the tail vein 60 min (Exp. 1) or 30 min (Exp. 2,3) after i.p. injection of 200 microliters DMSO (20 percent in saline) in control group; or forskolin (5 mM) prepared in DMSO (100 percent) and diluted to 1 mM with saline just before injection. The mice were sacrificed after 9 days (Exp. 1) or 14 days (Exp. 2,3) and the lungs removed for examination. The tumor foci were counted with the help of a dissecting microscope. No overt signs of toxicity were seen in these mice after the i.p. administration of forskolin. Fig. 2 presents typical specimens of lungs from untreated and forskolin-treated mice of experiments 2 and 3. Examination under a dissecting microscope revealed that the tumor foci in the forskolin-treated mice were smaller and more superficial than in the untreated mice, which were larger and more deeply embedded. A summary of these experiments is provided in Table 1 below.
TABLE I
CONTROL MICE
No. of pulmonary Median tumor foci* number
Experiment 1 62,69,103,189, 189
(2 x 105 cells/mouse) 191,281,350
FORSKOLIN-TREATED MICE
No. of pulmonary Median P tumor foci number value
0, 17,31 ,32,47,89 3.1 0.014
CONTROL MICE
No. of pulmonary Median tumor foci number
Experiment 2 6,111,189,210,248, 210 (3 x 105 cells/mouse) 267,276
FORSKOLIN-TREATED MICE
No. of pulmonary Median P tumor foci number value
0,0,1,1,48,115 1 0.004
CONTROL MICE
No. of pulmonary Median tumor foci number
Experiment 3 >600 in each of >600
(3 x 105 cells/mouse) nine mice**
FORSKOLIN-TREATED MICE
No. of pulmonary Median P tumor foci number value
0,0,81,123,176, 149-5 <0.001 219,250,281
*Each value is the no. of pulmonary foci per mouse.
**Estimated value. The lungs were fuly occupied by tumor foci. (See Fig. 3, IIA). In experiment 3, the mice were younger (about 5 weeks old). EXAMPLE III The in vitro experimental procedure of Example I above was repeated using a combinatiop of forskolin and oxagrelate. In this example the cell suspension was added to platelet-rich plasma incubated with a mixture of forskolin and oxagrelate. It was found that low concentrations of oxagrelate (20 micromolar) and forskolin (0.4 micromolar) which were only slightly inhibitory alone (20 percent) acted synergistically (95 percent inhibition) when mixed with the platelets.
EXAMPLE IV The in vivo experimental procedure of Example II above was also repeated using a combination of forskolin and oxagrelate. Intraperitoneal injections of the combination (oxagrelate: 40-45 mb/kg and forskolin: 1-1.5 mg/kg) 30 minutes before tail vein injections of the B16-F10 tumor cells reduced tumor colonization in the lungs of the mice 40 to 70 percent.

Claims

CLAIMSWhat is claimed is:
1. The use of a forskolin cαnpound, having the formula:
where R1 is hydrogen or a hydroxy or alkoxy, sulfonate or carbonate group; where R2 is a hydroxy, carbonate, acetyl, or acetoxy or alkanoyl group; where R3 is a hydroxy, carbonate, acetyl or acetoxy group; where R4 is hydrogen or a hydroxy or alkoxy, sulfonate or carbonate group; where R5 is either double-bonded oxygen or separately bound hydrogen and hydroxy groups; and where R6 is a lower alkene or oxygen, for the reduction of tumor metastasis.
2. The use of a forskolin compound having the formula:
for the reduction of tumor metastasis.
3. The use of a composition comprising a forskolin compound having the formula:
where R1 is hydrogen or a hydroxy or alkoxy, sulfonate or carbonate group; where R2 is a hydroxy, carbonate, acetyl, or acetoxy or alkanoyl group; where R3 is a hydroxy, carbonate, acetyl or acetoxy group; where R4 is hydrogen or a hydroxy or alkoxy, sulfonate or carbonate group; where R5 is either double-bonded oxygen or separately bound hydrogen and hydroxy groups; and where R6 is a lower alkene or oxygen, and at least one further compound chosen from the group of p-nitrobenzylthionosine, dilazep, theophylline analogs, dipyridamole, dipyridamole analogs, oxagrelate, papaverine, adenosine analogs, N6-phenyladenosine and prostacyclins, for the reduction of tumor metastasis..
4. The use of a composition comprising a forskolin compound having the formula:
and at least one further compound chosen from the group of p-nitrobenzylthionosine, dilazep, theophylline analogs, dipyridamole, dipyridamole analogs, oxagrelate, papaverine, adenosine analogs, N6-phenyladenosine and prostacyclins, for the reduction of tumor metastasis.
5. A pharmaceutical composition comprising a forskolin compound having the formula
and at least one further compound chosen from the group of p-nitrobenzylthionosine, dilazep, theophylline analogs, dipyridamole, dipyridamole analogs, oxagrelate, papaverine, adenosine analogs, N6-phenyladenosine and prostacyclins, for the reduction of tumor metastasis.
6. A pharmaceutical composition comprising a forskolin compound having the formula:
and at least one further compound chosen from the group of p-nitrobenzylthionosine, dilazep, theophylline analogs, dipyridamole, dipyridamole analogs, oxagrelate, papaverine, adenosine analogs, N6-phenyladenosine and prostacyclins, for the reduction of tumor metastasis.
EP19850900412 1983-12-14 1984-12-13 Treatment of metastasis Withdrawn EP0167567A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56118283A 1983-12-14 1983-12-14
US561182 1995-11-20

Publications (1)

Publication Number Publication Date
EP0167567A1 true EP0167567A1 (en) 1986-01-15

Family

ID=24240966

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19850900412 Withdrawn EP0167567A1 (en) 1983-12-14 1984-12-13 Treatment of metastasis

Country Status (2)

Country Link
EP (1) EP0167567A1 (en)
WO (1) WO1985002616A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3502686A1 (en) * 1985-01-26 1986-08-14 Hoechst Ag, 6230 Frankfurt METHOD FOR THE PRODUCTION OF LABDAN DERIVATIVES AND THEIR USE AS MEDICINAL PRODUCTS
DE3502685A1 (en) * 1985-01-26 1986-09-04 Hoechst Ag, 6230 Frankfurt FORSKOLIN, ITS ANALOGS AND DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF BY MEANS OF MICROBIAL CONVERSIONS AND THE USE OF THESE COMPOUNDS AS MEDICINAL PRODUCTS
FR2613935B1 (en) * 1987-04-15 1989-12-01 Roussel Uclaf COMBINATION CONTAINING, AS ACTIVE INGREDIENTS, A CENTRAL ANALGESIC AND FORSKOLIN
IN166900B (en) * 1987-06-03 1990-08-04 Hoechst India

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517200A (en) * 1982-12-27 1985-05-14 Schering-Plough Corporation Method for treating allergic reactions with forskolin
US4476140A (en) * 1983-05-16 1984-10-09 Yale University Composition and method for treatment of glaucoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8502616A1 *

Also Published As

Publication number Publication date
WO1985002616A1 (en) 1985-06-20

Similar Documents

Publication Publication Date Title
US4751224A (en) Treatment of metastasis
Harrison et al. Alterations of vascular reactivity in atherosclerosis
Agarwal et al. Forskolin: a potential antimetastatic agent
Ferrero et al. Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium
Casals-Stenzel Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shock
Beasley et al. Endotoxin inhibits contraction of vascular smooth muscle in vitro
JP6669762B2 (en) Composition for use in enhancing engraftment efficiency of hematopoietic stem cells after transplantation
KR20010015807A (en) Use of 9-deoxy-2&#39;,9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1&#39;,3&#39;-interphenylene)-13,14-dihydro-prostaglandin f1 to treat peripheral vascular disease
JP2004505047A (en) Cancer treatment by combined therapy
US6616925B1 (en) Combined preparation for the treatment of neoplasic diseases or of infectious diseases
JP2008291040A (en) Nicotine receptor agonist in stem cell and progenitor cell recruitment
JP3071820B2 (en) Use of lipoxin A (4) and its derivatives as antagonists for anaphylaxis slow-reacting substances
KR20010072957A (en) Activation and protection of t-cells(cd4+ and cd8+) using an h2 receptor agonist and other t-cell activating agents
BR112013017878B1 (en) Method to improve hematopoietic stem cell engraftment and derived compositions
CA1220139A (en) Compounds, compositions and method of treatment for improving circulatory performance
EP0167567A1 (en) Treatment of metastasis
KR100707051B1 (en) Antihelminthic anthraquinones and method of use thereof
Benzi et al. Effect of lysergide and nimergoline on glucose metabolism investigated on the dog brain isolated in situ
JPH09507490A (en) Vanadate compounds for the treatment of proliferative disorders, metastases and drug resistant tumors
IL237119A (en) Heterocyclyl carboxamides for treating viral diseases
Schirner et al. The prostacyclin analogue cicaprost inhibits metastasis of tumours of R 3327 MAT Lu prostate carcinoma and SMT 2A mammary carcinoma
Richel et al. Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia
DRAGO et al. Control of metastases in the Nb rat prostatic adenocarcinoma model
US5895785A (en) Treatment and prevention of disorders mediated by LA-paf or endothelial cells
Hatori et al. Differences in infarct size with lidocaine as compared with bretylium tosylate in acute myocardial ischemia and reperfusion in pigs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB LI LU NL SE

17P Request for examination filed

Effective date: 19851202

17Q First examination report despatched

Effective date: 19870820

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19871231

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PARKS, ROBERT, E., JR.

Inventor name: AGARWAL, KAILASH, C.